Additional file 7: of Safety, tolerability, pharmacokinetics, and pharmacodynamics of the afucosylated, humanized anti-EPHA2 antibody DS-8895a: a first-in-human phase I dose escalation and dose expansion study in patients with advanced solid tumors
Kohei Shitara
Taroh Satoh
Satoru Iwasa
Kensei Yamaguchi
Kei Muro
Yoshito Komatsu
Tomohiro Nishina
Taito Esaki
Jun Hasegawa
Yasuyuki Kakurai
Emi Kamiyama
Tomoko Nakata
Kota Nakamura
Hayato Sakaki
Ichinosuke Hyodo
10.6084/m9.figshare.9631238.v1
https://springernature.figshare.com/articles/figure/Additional_file_7_of_Safety_tolerability_pharmacokinetics_and_pharmacodynamics_of_the_afucosylated_humanized_anti-EPHA2_antibody_DS-8895a_a_first-in-human_phase_I_dose_escalation_and_dose_expansion_study_in_patients_with_advanced_solid_tumo/9631238
Disposition of patients. â One patient was excluded from the efficacy analysis set because no efficacy data were available. âĄOne patient was excluded from the PK analysis set because no PK data were available. Abbreviation: PK, pharmacokinetics. (TIF 224 kb)
2019-08-15 05:01:24
Erythropoietin-producing hepatocellular receptor A2
Gastric cancer
Esophageal cancer
Advanced solid tumors
DS-8895a
Antibody-dependent cellular cytotoxicity
Phase I study